Journal: Neuropsychiatric Disease and Treatment

Article Title: Investigation on Inhibiting SPHK - S1P Pathway to Improve ADHD Model Rats Behavior via Lipidomics

doi: 10.2147/NDT.S530564

Figure Lengend Snippet: Changes in gene and protein expression following SKI II intervention ( A ) Relative expression levels of Sphk1 mRNA. ( B ) Relative expression levels of Sphk2 mRNA. ( C ) Representative Western blot bands showing SPHK1/GAPDH and SPHK2/GAPDH ratios. ( D ) Relative protein levels of SPHK1. ( E ) Relative protein levels of SPHK2. ( F ) S1P levels in the PFC were measured by ELISA. ( G ) Representative Western blot bands showing DBH/GAPDH, MAOA/GAPDH, TH/GAPDH, and DRD1/GAPDH ratios. ( H ) Relative protein levels of DBH. Each value represents the mean ± standard deviation of at least three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Primary antibodies were incubated overnight at 4°C in the following concentrations: GAPDH (1:10,000; Proteintech, China), β-Tubulin (1:4000; Proteintech), CERK (1:1000; ABclonal, China), CERS1 (1:1000; Huamei Bio, China), SMPD1 (1:1500; ABclonal), SGMS1 (1:1000; ABclonal), HEXA (1:700; ABclonal), SPHK1 (1:1000; Proteintech), SPHK2 (1:1000; Wanlei Bio), DBH (1:500; ABclonal), DRD1 (1:700; Proteintech), MAOA (1:1000; Proteintech), and TH (1:2000; Proteintech).

Techniques: Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Investigative Ophthalmology & Visual Science

Article Title: Distinct Transcriptomic Profiles of Cultured Anterior and Posterior Populations of Human Infant Scleral Fibroblasts: Including Dopamine Receptors

doi: 10.1167/iovs.66.5.29

Figure Lengend Snippet: D1-like receptor activity promotes the inhibitory effect of DA on cell contraction, whereas D2-like receptor activity, particularly that of DRD2 in the posterior sclera, impedes it. ( a – p ) The cell contraction rates at 24 hours for anterior ( a – h ) and posterior ( i – p ) scleral fibroblasts from HSF12 and HSF13 were measured following treatment with a range of DA receptor antagonists and agonists, administered 1 hour prior to the addition of DA. One experiment was conducted with three replicate wells for each compound tested, using two biological samples (HSF12 and HSF13; total n = 6). Results from the two cell lines were averaged and presented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (two-way ANOVA).

Article Snippet: The antibodies used were as follows: Dopamine Receptor D1 Rabbit mAb (381747; Zen-Bioscience), DRD2 polyclonal antibody (55084-1-AP; Proteintech, Rosemont, IL, USA), Dopamine Receptor D3 Rabbit mAb (382983; Zen-Bioscience), DRD4 Rabbit polyclonal antibody (28094-1-AP; Proteintech), Dopamine Receptor D5 Rabbit pAb (820522; Zen-Bioscience), GAPDH (7E4) Mouse mAb (200306-7E4; Zen-Bioscience), Beta Tubulin Polyclonal antibody (10094-1-AP; Proteintech), Goat anti-Rabbit IgG(H&L) (HRP conjugate) (511203; Zen-Bioscience), and Goat anti-Mouse IgG (H&L) (HRP conjugate) (511103; Zen-Bioscience).

Techniques: Activity Assay